Background: Chemotherapy at the end of life is a complex and challenging problem in medical oncology. Patients affected by ovarian cancer (OC) often experience a chronicization and slow progression of their disease, and chemotherapy is proposed until the end of life. Methods: We retrospectively analyzed data from patients affected by OC treated at our department and having died in the period between 2007 and 2017 and evaluated the frequency of antineoplastic treatments until the end of life, the chemotherapy-related toxicity, mortality, and the most frequent palliative care measure adopted. Results: A total of 110 OC deaths, after a median overall patient survival of 52.8 months (range 4–232), were analyzed. 77.3% of the patients presented with FIGO stage IIIC OC at diagnosis and 12.7% with FIGO stage IV OC. 89% of the histological types were serous papillary. The median age was 55 years (range 31–82) at diagnosis and 60 years (range 33–84) at death. Of the 110 patients analyzed, 85 (77%) had undergone chemotherapy over the last 3 months of life and 38% had chemotherapy even during the last month of life. The overwhelming majority of patients (81%) needed supportive therapies. Despite the treatments received, the majority of the patients died at home, 19% died in hospital, and only 4.5% died in hospice. The quality of life of these patients decreased dramatically in the last 30 days, but best supportive care improved the symptoms. Conclusions: End-of-life chemotherapy for OC patients is a thorny problem. More studies and a multidisciplinary approach are needed to better treat these patients.

1.
Torre
LA
,
Bray
F
,
Siegel
RL
,
Ferlay
J
,
Lortet-Tieulent
J
,
Jemal
A
.
Global cancer statistics, 2012
.
CA Cancer J Clin
.
2015
Mar
;
65
(
2
):
87
108
.
[PubMed]
0007-9235
2.
Chang
SJ
,
Bristow
RE
,
Chi
DS
,
Cliby
WA
.
Role of aggressive surgical cytoreduction in advanced ovarian cancer
.
J Gynecol Oncol
.
2015
Oct
;
26
(
4
):
336
42
.
[PubMed]
2005-0380
3.
Dinkelspiel
HE
,
Champer
M
,
Hou
J
,
Tergas
A
,
Burke
WM
,
Huang
Y
, et al
Long-term mortality among women with epithelial ovarian cancer
.
Gynecol Oncol
.
2015
Aug
;
138
(
2
):
421
8
.
[PubMed]
0090-8258
4.
Jayson
GC
,
Kohn
EC
,
Kitchener
HC
,
Ledermann
JA
.
Ovarian cancer
.
Lancet
.
2014
Oct
;
384
(
9951
):
1376
88
.
[PubMed]
0140-6736
5.
Wright
JD
,
Chen
L
,
Tergas
AI
,
Patankar
S
,
Burke
WM
,
Hou
JY
, et al
Trends in relative survival for ovarian cancer from 1975 to 2011
.
Obstet Gynecol
.
2015
Jun
;
125
(
6
):
1345
52
.
[PubMed]
0029-7844
6.
Giornelli
GH
.
Management of relapsed ovarian cancer: a review
.
Springerplus
.
2016
Jul
;
5
(
1
):
1197
.
[PubMed]
2193-1801
7.
National quality forum : national voluntary consensus standards for quality of cancer care. May
2009
Cancer Care Phase I-II link: http://www.qualityforum.org/publications/2009/05/National_voluntary_consensus_standards_for_Quality_of_Cancer_Care.aspx
8.
American society of clinical oncology institute for quality : summary of current QOPI measures link: https://practice.asco.org/quality-improvement/quality-programs/quality-oncology-practice-initiative
9.
Lopez-Acevedo
M
,
Havrilesky
LJ
,
Broadwater
G
,
Kamal
AH
,
Abernethy
AP
,
Berchuck
A
, et al
Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer
.
Gynecol Oncol
.
2013
Jul
;
130
(
1
):
156
61
.
[PubMed]
0090-8258
10.
Hui
D
,
Kim
SH
,
Roquemore
J
,
Dev
R
,
Chisholm
G
,
Bruera
E
.
Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients
.
Cancer
.
2014
Jun
;
120
(
11
):
1743
9
.
[PubMed]
0008-543X
11.
Urban
RR
,
He
H
,
Alfonso
R
, Hardesty MM3, Goff BA4.. The end of life costs for Medicare patients with advanced ovarian cancer. Gynecol Oncol. . doi: .(8)
12.
Yun
YH
,
Park
YS
,
Lee
ES
,
Bang
SM
,
Heo
DS
,
Park
SY
, et al
Validation of the Korean version of the EORTC QLQ-C30
.
Qual Life Res
.
2004
May
;
13
(
4
):
863
8
.
[PubMed]
0962-9343
13.
Lee
Y
,
Lim
MC
,
Kim
SI
,
Joo
J
,
Lee
DO
,
Park
SY
.
Comparison of Quality of Life and Sexuality between Cervical Cancer Survivors and Healthy Women
.
Cancer Res Treat
.
2016
Oct
;
48
(
4
):
1321
9
.
[PubMed]
1598-2998
14.
Brown
AJ
,
Sun
CC
,
Prescott
LS
.
Taylor JS1, Ramondetta LM1, Bodurka DC1. Missed opportunities: patterns of medical care and hospice utilization among ovarian cancerpatients
.
Gynecol Oncol
.
2014
Nov
;
135
(
2
):
244
8
.
[PubMed]
0090-8258
15.
O’Brien
ME
,
Borthwick
A
,
Rigg
A
,
Leary
A
,
Assersohn
L
,
Last
K
, et al
Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients
.
Br J Cancer
.
2006
Dec
;
95
(
12
):
1632
6
.
[PubMed]
0007-0920
16.
Rodriguez-Freixinos
V
,
Fariñas-Madrid
L
,
Gil-Martin
M
,
Barretina-Ginesta
P
,
Romeo
M
,
Villacampa
G
, et al
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients
.
Gynecol Oncol
.
2018
Dec
;
•••
:
[PubMed]
0090-8258
17.
Pirl
WF
,
Greer
JA
,
Irwin
K
,
Lennes
IT
,
Jackson
VA
,
Park
ER
, et al
Processes of discontinuing chemotherapy for metastatic non-small-cell lung cancer at the end of life
.
J Oncol Pract
.
2015
May
;
11
(
3
):
e405
12
.
[PubMed]
1554-7477
18.
Agarwal
R
,
Epstein
AS
.
Palliative care and advance care planning for pancreas and other cancers
.
Linchuang Zhongliuxue Zazhi
.
2017
Jun
;
6
(
3
):
32
.
[PubMed]
1009-0460
19.
Dvoretsky
PM
,
Richards
KA
,
Angel
C
,
Rabinowitz
L
,
Beecham
JB
,
Bonfiglio
TA
.
Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer
.
Hum Pathol
.
1988
Nov
;
19
(
11
):
1273
9
.
[PubMed]
0046-8177
20.
Landrum
LM
,
Blank
S
,
Chen
LM
,
Duska
L
,
Bae-Jump
V
,
Lee
PS
, et al
Comprehensive care in gynecologic oncology: the importance of palliative care
.
Gynecol Oncol
.
2015
May
;
137
(
2
):
193
202
.
[PubMed]
0090-8258
21.
Wright
AA
,
Hatfield
LA
,
Earle
CC
,
Keating
NL
.
End-of-life care for older patients with ovarian cancer is intensive despite high rates of hospice use
.
J Clin Oncol
.
2014
Nov
;
32
(
31
):
3534
9
.
[PubMed]
0732-183X
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.